During the last quarter of a century bisphosphonates have become a major tool in the management of bone disease second only to vitamin d a great deal of research on these agents has been carried out by investigators from a variety of disciplines but until now the resulting information had not been presented in a systematic fashion addressing the needs of clinicians basic researchers and . But treating patients with bisphosphonates during bone healing is controversial because osteoclasts are important for remodeling callus into cortical bone several studies have addressed the effects of bisphosphonates on indirect bone healing the results are inconsistent. Bisphosphonate could be administrated orally or intravenously it reduces bone resorption mechanism of action bisphosphonate binds to the mineral component of the bone and inhibits enzymes ie farnesyl pyrophosphate synthase that is responsible for bone formation recruitment and osteoclast function. Bisphosphonates are drugs that affect bone turnover and have been used in the treatment of several conditions related to the skeleton system since the start of the 2000s1 less potent bisphosphonates such as alendronate and risedronate are administered orally to control non malignant bone
How it works:
1. Register Trial Account.
2. Download The Books as you like ( Personal use )